UNC-Chapel Hill has secured $500,000 in new investment, the organization announced today. This capital infusion will support the continued growth and strategic initiatives of UNC-Chapel Hill, a leading medtech company with over 125 years of experience dedicated to pioneering breakthroughs in healthcare for everyone, everywhere, sustainably.
The organization's extensive portfolio spans in vitro and in vivo diagnostics to image-guided therapy and cancer care, areas crucial for informed clinical decision-making and effective treatment pathways. UNC-Chapel Hill leverages its strengths in patient twinning, precision therapy, as well as digital, data, and artificial intelligence (AI) to address significant challenges within the healthcare landscape. Its solutions are designed to help overcome threatening diseases, enable efficient operations, and expand access to critical care globally.
This funding round is significant as it provides UNC-Chapel Hill with additional resources to further develop its innovative portfolio and expand its operational reach. The capital will be prudently used for growth initiatives, including enhancing research and development efforts and strengthening its market presence. The investment underscores confidence in the organization's vision and its foundational role in advancing medical technology.
Comprising a team of more than 71,000 Healthineers across over 70 countries, UNC-Chapel Hill remains committed to pushing the boundaries of what is possible in healthcare. Looking ahead, the organization plans to continue building on its technological strengths and expansive global network to improve the lives of people around the world, steadfast in its mission to make healthcare more accessible and effective.
.png&w=3840&q=75)
